(Date:11/6/2009)...ire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE:...John Docherty, president and chief operating offic...ual Investor Summit on November 10, 2009 at 4:00 P...erty will provide an overview of the Company,s lea...cal Interferon Alpha-2b. The slide show portion o...
(Date:11/6/2009)...swire-FirstCall/ -- ,, 3Q09 Corporate Highli....U. Marketing Authorization to Astellas Pharma Eur... readiness activities Expanded management team to... Director, Commercial Operations Appointed Bradfo...ttee chairman , Upcoming 2009 Milestones: ...
(Date:11/6/2009)...ire/ -- Intarcia Therapeutics, Inc. delivered two ...ontinuous delivery of exenatide) program for the t...abetes Technology Meeting in San Francisco, CA: ,...050301/SFTU126LOGO ) ,, Continuous Subcutaneo...a Glucose, HbA1c and Reduces Weight in a 28-day Ph...
(Date:11/5/2009)...swire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC ) ...d quarter ended September 30, 2009. GenVec reporte... the three months ended September 30, 2009 compare...in the comparable quarter of 2008. For the nine mo...as $14.1 million ($0.15 per share), compared to a ...
Breaking Biology Technology:Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 3NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6(Date:11/6/2009)...150th anniversary this month of the publication of...of Biological Sciences (AIBS) is publishing open a...win and his historic insights into evolution. , T...ity of California, Berkeley, and James T. Costa of...en Myths About Charles Darwin," appeared in the Oc...
(Date:11/5/2009)...ciation of Biology Teachers (NABT) will recognize ...nces at Naugatuck Valley Community College (NVCC) ... Education Award during the NABT annual profession...r 2009 in Denver, Colorado. , The Evolution Educ...te of Biological Sciences,(AIBS) and Biological S...
(Date:11/4/2009)...ws in natural science) , United States Using L...ater today than it did 35 years ago, despite a 30 ... are partly attributable to alternative cooling me...n systems. According to the latest USGS water use ...d States goes to cooling thermoelectric power plan...
Breaking Biology News(10 mins):Biologists, educators recognize excellence in evolution education 2USGS science picks 2USGS science picks 3USGS science picks 4USGS science picks 5USGS science picks 6USGS science picks 7Prostate cancer patients on hormone therapy at increased risk for various heart diseases 57921 1Prostate cancer patients on hormone therapy at increased risk for various heart diseases 57921 2Prostate cancer patients on hormone therapy at increased risk for various heart diseases 57921 3Prostate cancer patients on hormone therapy at increased risk for various heart diseases 57921 4Targeted heat therapy offers new standard treatment option for soft tissue sarcoma 57919 1Targeted heat therapy offers new standard treatment option for soft tissue sarcoma 57919 2Targeted heat therapy offers new standard treatment option for soft tissue sarcoma 57919 3Targeted heat therapy offers new standard treatment option for soft tissue sarcoma 57919 4Summits Alone Wont Feed the Hungry Aid Agency Says 57917 1Summits Alone Wont Feed the Hungry Aid Agency Says 57917 2...hemical Inkjet Printer) is a revolutionary new app...acroarray Analysis, developed in conjunction with ...trategy compliments established protocols in resol...lectric point and apparent molecular weight). Howe...
RNase Inhibitor from Applied Biosystems
Goat Anti-Rat UGT1A7 (E-15) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
CAOSMC (C354-05) from European Collection of Cell Cultures (ECACC)
Biology Products: